Thalidomide maintenance in multiple myeloma

Article metrics

Thalidomide is frequently used in patients with newly diagnosed and relapsed multiple myeloma, but its role as maintenance therapy following autologous stem-cell transplantation has been an area of uncertainty. In this article we consider the efficacy of thalidomide maintenance therapy in multiple myeloma.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Spencer, A. et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J. Clin. Oncol. 27, 1788–1793 (2009).

  2. 2

    D'Amato, R. J., Loughman, M. S., Flynn, E. & Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl Acad. Sci.USA 91, 4082–4085 (1994).

  3. 3

    Vacca, A. et al. Bone marrow angiogenesis and progression in multiple myeloma. Br. J. Haematol. 87, 503–508 (1994).

  4. 4

    Singhal, S. et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341, 1565–1571 (1999).

  5. 5

    Palumbo, A. et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367, 825–831 (2006).

  6. 6

    Rajkumar, S. V., Blood, E., Vesole, D., Fonseca, R. & Greipp, P. R. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol. 24, 431–436 (2006).

  7. 7

    Stewart, A. K. et al. Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin. Cancer Res. 10, 8170–8176 (2004).

  8. 8

    Attal, M. et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108, 3289–3294 (2006).

  9. 9

    Barlogie, B. et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N. Engl. J. Med. 354, 1021–1030 (2006).

  10. 10

    Morgan, G. J. et al. Maintenance thalidomide may improve progression free but not overall survival; results from the myeloma IX maintenance randomisation [abstract]. Blood (ASH Annual Meeting Abstracts) 112, 656 (2008).

Download references

Author information

Correspondence to Jacob P. Laubach.

Ethics declarations

Competing interests

P. Richardson is an Advisory Board member for Celgene and Millenium. K Anderson is a Consultant and receives research/grant support from Celgene and Millenium.

Rights and permissions

Reprints and Permissions

About this article

Further reading